Nhwa Pharma invests $3.5m in NeuroThree Therapeutics

Jiangsu Nhwa Pharmaceutical (SZSE:002262) announced a $3.5 million strategic investment in NeuroThree Therapeutics, Inc., a Cayman Islands-registered biopharmaceutical company specializing in innovative CNS therapies. Nhwa will acquire 12.5 million Pre-A series preferred shares, representing a 10.448% equity stake in NeuroThree. The investment aims to accelerate the R&D of innovative drugs and enhance Nhwa's drug development efficiency. NeuroThree focuses on developing transformative treatments for neurological disorders, with a pipeline including clinical-stage small molecule drugs for epilepsy and preclinical siRNA programs. The investment will be funded by Nhwa's own capital and will not affect the company's equity structure. The deal was approved by Nhwa’s board of directors on March 5th, 2025.